Metsera, Inc.

Pfizer Inc.

Pharmaceutical giant Pfizer, best known for its COVID-19 vaccine Pfizer has <a href="https://www.businesswire.com/news/home/20250922965053/en/Pfizer-to-Acquire-Metsera-and-its-Next-Generation-Obesity-Portfolio?utm_source=chatgpt.com">revealed </a>it is buying weight-loss drug developer Metsera for $4.9 billion, a move that will allow Pfizer to step up its bet on solutions in the popular obesity treatment area, AP <a href="https://apnews.com/article/pfizer-metsera-obesity-treatments-e85141f89b670b8d9a7520de3a2fd7c5">notes</a>.

Pfizer will buy a company that develops obesity remedies. Its shares soared 60%

Sarepta Therapeutics, Inc.

Shares of Sarepta Therapeutics, a small-cap developer of genetic medicines to treat rare neuromuscular and central nervous system diseases, soared 14% yesterday, July 29. The driver of the gains was the announcement that U.S. health regulators had authorized the biotech to resume shipments of its gene therapy that accounts for the majority of its revenue. Still, analysts&nbsp;caution that sales momentum will need to be maintained for the company to make a looming debt repayment.&nbsp;

Shares in biotech Sarepta soar after FDA allows shipments of Elevidys to resume


Eli Lilly and Company

Novo Nordisk A/S

AstraZeneca PLC

At least a dozen companies are looking for a way to reduce muscle mass loss when taking weight loss drugs

#Drugs: 3

Pfizer will buy a company that develops obesity remedies. Its shares soared 60%

Shares in biotech Sarepta soar after FDA allows shipments of Elevidys to resume

Eli Lilly is entering a market valued at $30 billion, can it beat the competition?